📱#ASCOAI: Human-supervised #AI could support nurse-led #oncology triage by identifying low-acuity calls and drafting clinical notes. ➡️ LLMs generated documentation faster than trainees, but prospective validation is needed. 🔗 ascoai.org/articles/2026/10/… #ASCOQLTY26 #AIinOncology

🧬 Despite higher rates of cardiovascular and kidney disease, adults with #Diabetes and a history of #Cancer reported lower use of injectable GLP-1 RAs. 🔸Bismarck C. Odei, MD | @JAMANetworkOpen Explore the findings ➡️ ascopost.com/news/october-20…

💉Phase III INTerpath-001 trial: A personalized mRNA cancer vaccine plus pembrolizumab reduced the risk of recurrence or death by 42% vs pembrolizumab alone in patients with high-risk #Melanoma after surgery. ▪ @ProfGLongMIA | #ESMO26 | @myESMO 🔗 ascopost.com/news/october-20…

🚹 Triplet therapy improved long-term survival in metastatic castration-sensitive #ProstateCancer. In PEACE-1, 8-year OS was 40.3% with abiraterone + ADT ± docetaxel vs 27.1% with standard therapy alone. 🔹Karim Fizazi, MD, PhD | | #ESMO26 | @myESMO 🔗 ascopost.com/news/october-20…

📝 #ASCOAI: Ambient #AI scribes are entering oncology workflows, but adoption varies. New @ClevelandClinic data highlight differences in use among medical oncology, hematology, and radiation oncology clinicians from a large-scale deployment. 🔗️ ascoai.org/articles/2026/10/…

💻Expanding access to oncology expertise could help address gaps in #CancerCare. New findings suggest remote expert case reviews can identify opportunities to improve treatment, including for patients in nonurban settings. 🔹Debra Wong, MD | #ASCOQLTY26 ascopost.com/news/october-20…

🩸New phase III VERIFY findings highlight rusfertide benefits in patients with #PolycythemiaVera: ⬆️Improved hematocrit control 📉Fewer phlebotomies ⬇️Reduced fatigue and symptom burden 🥼@KuykendallMd | @JCO_ASCO | #MPNsm 🔗 ascopost.com/news/october-20…

🚨 #FDAApproval: The @FDA has granted approval for talazoparib (Talzenna) + enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation–naive/sensitive #ProstateCancer. Approval supported by findings from the TALAPRO-3 trial. 🔗 ascopost.com/news/october-20…

🏆 @theNAMedicine has elected 100 new members for 2026, recognizing outstanding contributions to medical science, health care, and public health. 🌐 The new class includes 90 U.S. and 10 international members. Meet the inductees ➡️ ascopost.com/news/october-20…

🚭 Financial incentives may improve smoking cessation among patients referred for #LungCancer screening. In a trial of 3,259 underserved adults, sustained abstinence rates were 8.8% with incentives vs 4.3% with usual care. ▪️@JHartMD | @JAMANetwork 🔗 ascopost.com/news/october-20…

Catch up on the latest #AI in #oncology news: 🔹 @FDA-cleared #BreastCancer risk tool 🔹LLMs in oncology telephone triage 🔹Chatbot improves hereditary #cancerrisk awareness 🎥 Watch this week's brief: ascoai.org/videos/weekly-bri…

🌎 Geographic disparities limit access to #BreastCancer clinical trials. A new study found that 76% of U.S. counties had no active TNBC trials, highlighting significant gaps in research access. 🔹Research from @UTMDAnderson & @ASCO ascopost.com/news/october-20…

🧫 The NRG-BR002 trial found that adding metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic #BreastCancer. ▪️Steven J. Chmura, MD, PhD | @JCO_ASCO ascopost.com/news/october-20…

🖥️ #ASCOAI: Personalized PSA monitoring may improve #ProstateCancer follow-up. An #AI model incorporating PSA kinetics, clinical data showed promising accuracy in identifying recurrence risk after radiotherapy. #ASTRO26 ➡️External validation is underway 🔗 ascoai.org/articles/2026/10/…

📄Experts call for stronger quality-of-life reporting in adjuvant #Cancer trials. New recommendations emphasize measuring clinically meaningful deterioration, duration, & recovery rather than relying on average scores. 🔸Ian Tannock, MD | @TheLancetOncol ascopost.com/news/october-20…

🧠 Updated phase I data show promising survival with bivalent #CARTcell therapy in recurrent #Glioblastoma. Among 18 patients, the median OS was 12 months, with no delayed-onset or unexpected toxicities observed. ▪️@StephenBagleyMD | #ASCO26 🔗 ascopost.com/news/october-20…

📰 Top stories in the October issue of The ASCO Post: 🔹Bivalent #CARTcell therapy in recurrent #glioblastoma 🔹B7-H4–targeted ADCs in #ovariancancer 🔹Evolving treatment options for relapsed #DLBCL 🔹#GLP1 RAs & #BreastCancer risk Explore the issue ➡️ ascopost.com/issues/october-…

📱 #ASCOAI: Personalized digital education may strengthen hereditary #Cancer counseling. The AYA-RISE chatbot improved risk comprehension in young patients using guideline-based content and predefined conversations, not generative #AI. Learn more ➡️ ascoai.org/articles/2026/10/…

🫁 Claudia Henschke, PhD, MD, helped transform #LungCancer screening through pioneering research on early detection with low-dose CT. @RajaFlores reflects on her extraordinary career, scientific legacy, and personal impact. Read the full dedication 👉 ascopost.com/news/october-20…

🚨 #FDAApproval: The @FDA has granted traditional approval to pembrolizumab (Keytruda) and Keytruda Qlex for previously treated, unresectable or metastatic TMB-H solid tumors (≥13 mut/Mb) with no satisfactory alternatives. 🔗 ascopost.com/news/october-20…